Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (31-40 of 192) with videos related to

Pageof 20
Sort By:
Antiviral Research|February 24, 2016
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patientsAndrea Giacomelli, Letizia Oreni, Marco Franzetti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 19, 2017
Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, ItalyAnna L Ridolfo, Letizia Oreni, Paolo Vassalini, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort studyMarco Bongiovanni, Teresa Bini, Federica Tordato, et al.
Journal of the International AIDS Society|November 15, 2014
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimensAndrea Giacomelli, Letizia Oreni, Marco Franzetti, et al.
The Journal of Antimicrobial Chemotherapy|February 14, 2004
Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolatesElisabetta Bulgheroni, Paola Citterio, Francesco Croce, et al.
The New Microbiologica|March 3, 2018
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trialElisa Colella, Dario Cattaneo, Laura Galli, et al.
AIDS (London, England)|December 20, 2007
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scoresSharon L Walmsley, Laurent Cotte, Stefano Rusconi, et al.
AIDS (London, England)|August 28, 2007
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESISTFrançois Raffi, Manuel Battegay, Stefano Rusconi, et al.
Pathogens (Basel, Switzerland)|November 25, 2023
Invasive and Non-Invasive Human Salmonellosis Cases Admitted between 2015 and 2021 in Four Suburban Hospitals in the Metropolitan Area of Milan (Italy): A Multi-Center Retrospective StudyGabriele Pagani, Marco Parenti, Marco Franzetti, et al.
AIDS Research and Human Retroviruses|November 28, 2013
Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virusPamela Tau, Alessandro Mancon, Davide Mileto, et al.
Pageof 20

Showing results (31-40 of 192) with videos related to

Sort By:
Pageof 20
Antiviral Research|February 24, 2016
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patientsAndrea Giacomelli, Letizia Oreni, Marco Franzetti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 19, 2017
Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, ItalyAnna L Ridolfo, Letizia Oreni, Paolo Vassalini, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort studyMarco Bongiovanni, Teresa Bini, Federica Tordato, et al.
Journal of the International AIDS Society|November 15, 2014
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimensAndrea Giacomelli, Letizia Oreni, Marco Franzetti, et al.
The Journal of Antimicrobial Chemotherapy|February 14, 2004
Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolatesElisabetta Bulgheroni, Paola Citterio, Francesco Croce, et al.
The New Microbiologica|March 3, 2018
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trialElisa Colella, Dario Cattaneo, Laura Galli, et al.
AIDS (London, England)|December 20, 2007
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scoresSharon L Walmsley, Laurent Cotte, Stefano Rusconi, et al.
AIDS (London, England)|August 28, 2007
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESISTFrançois Raffi, Manuel Battegay, Stefano Rusconi, et al.
Pathogens (Basel, Switzerland)|November 25, 2023
Invasive and Non-Invasive Human Salmonellosis Cases Admitted between 2015 and 2021 in Four Suburban Hospitals in the Metropolitan Area of Milan (Italy): A Multi-Center Retrospective StudyGabriele Pagani, Marco Parenti, Marco Franzetti, et al.
AIDS Research and Human Retroviruses|November 28, 2013
Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virusPamela Tau, Alessandro Mancon, Davide Mileto, et al.
Pageof 20